Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca CEO Designate Brennan Will Take Reins From McKillop In 2006

This article was originally published in The Pink Sheet Daily

Executive Summary

Selection of U.S. head David Brennan to succeed retiring CEO Tom McKillop was the result of a search that focused on internal candidates.

You may also be interested in...

Brennan’s Departure Not Expected To Disrupt Current Business Development Strategy At AstraZeneca

With the longtime CEO stepping down as of June 1, his successor will assume the challenge of handling generic challengers to several mature blockbuster products and the slow launch of Brilinta. The current business-development strategy, as reflected in a recent partnership and acquisition, is expected to stay in place for now.

AstraZeneca Says CEO McKillop Will Stay Through 2006 Despite Rumors

The British financial press speculates that McKillop could depart to become chairman of the Royal Bank of Scotland, but the bank says its current chairman could stay on for an additional five years. AstraZeneca board and McKillop have reached a new contract that would extend his employment beyond 2005, company says.

Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal

A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts